Success Stories: EB-1A Petition Approved for Associate Research Scientist in Mississippi in the Field of Pharmaceutical Sciences
Client’s Testimonial:
“Thanks a lot for everything. Yesterday evening, I received the approval notice from the USCIS!”
On January 6th, 2016, we received another EB1-A (Alien of Extraordinary Ability) approval for an Associate Research Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
Position at the Time of Case Filing: Associate Research Scientist
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Mississippi
Approval Notice Date: January 6th, 2016
Processing Time: 13 months, 24 days
North America Immigration Law Group (WeGreened.com), recently worked with an associate research scientist from India. His EB1A (Alien of Extraordinary Ability) petition, approved a little more than 13 months after filing, adds to our extensive list of green card success stories. As we took great care in explaining our client’s many accomplishments, we successfully presented a firm case to the USCIS. Included with the petition was a letter from one of our client’s independent recommenders, who wrote, “In my experience, work of the caliber performed by [Client] is a rare and valuable commodity due to the extraordinary level of education and leading edge expertise he brings to the table.”
Our client earned his Master’s and Ph.D. (both in Biochemistry) from prestigious universities in his country of birth before serving as an associate research scientist at a highly-regarded educational institution in the United States. As part of our case strategy, we highlighted his unique portfolio, including his specialty in natural products and compounds for integrative medicine. Our efforts conclusively established the ways in which his work has advanced the development of new drug discovery and aided the research of other scientists. As evidence of this, we emphasized our client’s citation record, which at the time of filing stood at 427. We also included accounts of his 18 journal papers. Additionally, we highlighted the weight of his insights by including data related to his peer review experience. In our submission of his EB-1A petition, we demonstrated that our client’s research, which has a significant impact on the country’s pharmaceutical industry, is of great benefit to the United States as whole.
We are pleased to congratulate our client on his professional successes and his newly approved EB-1A petition.